Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab

Hazim Bukamur, MD; Heather Katz, DO; Mohamed Alsharedi, MD; Akram Alkrekshi, MD, PgDip, MRCP(UK); Yousef R. Shweihat, MD; Nancy J. Munn, MD

Disclosures

South Med J. 2020;113(11):600-605. 

In This Article

Nivolumab-related Recurrent Pleural Effusion

Pleural effusions are a rare adverse event with immune checkpoint inhibitors, especially nivolumab. In the CheckMate 057 trial, a phase III trial comparing nivolumab versus docetaxel in advanced squamous NSCLC, 6% of the patients in the nivolumab arm and 3% in the docetaxel arm had a pleural effusion. No pleural effusions were reported as treatment-related serious adverse events.[6]

processing....